CLASS II ONGOING Drug recall · Reported 22 Oct 2025 · FDA Enforcement Report
Fasenra (benralizumab) Injection, 30 mg/mL recalled
Astrazeneca Pharmaceuticals is recalling Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, distributed nationwide in the US. The recall was initiated on 8 Oct 2025 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0028-2026
- FDA event ID
- 97760
- Recalling firm
- Astrazeneca Pharmaceuticals, Gaithersburg, MD
- Brand
- Fasenra
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 8 Oct 2025
- FDA classified
- 16 Oct 2025
- Reported
- 22 Oct 2025
- Type
- Voluntary: Firm initiated
- Customers notified by
- Reason category
- Sterility
- Drug class
- Injectable & IV Drugs
Timeline
| 8 Oct 2025 | Recall initiated by company | |
| 16 Oct 2025 | Classified by FDA | +8 days |
| 22 Oct 2025 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of Assurance of Sterility:
A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.
Product as listed by the FDA
Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30
Where it was distributed
Nationwide in the U.S
Questions about this recall
Why was it recalled?
Lack of Assurance of Sterility:
Which lots are affected?
Lot YJ0152, Expiry: 01/31/2028.
Where was it sold?
Nationwide in the U.S
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from Astrazeneca Pharmaceuticals
All 6| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Lynparza (olaparib) capsules 50 mg recalled | AstraZeneca Pharmaceuticals | Potency & Assay | Nationwide |
| Drug | CLASS I | Brilinta (ticagrelor) tablets, 90 mg Professional Sample recalledBrilinta | AstraZeneca Pharmaceuticals | Other | Nationwide |
| Drug | CLASS II | Tudorza Pressair (aclindinium bromide inhalation powder) recalled | AstraZeneca Pharmaceuticals | Other | Nationwide |
| Drug | CLASS II | Nexium¿ (esomeprazole magnesium), Delayed-Release capsules, 20 mg recalled | AstraZeneca Pharmaceuticals | Other | Nationwide |
| Drug | CLASS II | Merrem I.V. (meropenem for injection) meropenem equivalent vial recalled | AstraZeneca Pharmaceuticals | Other | PR |